On-Demand | Using Teriparatide: Combination and Sequential Therapies-Using Teriparatide: Combination and Sequential Therapies

Video Transcription

Video Summary

The webinar, led by Amal Shibli Rahal, an endocrinologist at the University of Iowa, focused on the intricacies of using teriparatide, an osteoanabolic agent, in combination or sequence with anti-resorptive agents like bisphosphonates and denosumab, in osteoporosis treatment. Teriparatide's use has been more liberal following the lifting of the black box warning regarding osteosarcoma.<br /><br />Key objectives included understanding the coupling between bone formation and resorption, and analyzing bone density responses in various drug sequence scenarios. One major point was that while teriparatide combined with a bisphosphonate doesn’t show significant benefit over teriparatide alone, layering a bisphosphonate after teriparatide may reopen the anabolic window, potentially enhancing bone density gains. The switch from bisphosphonates to teriparatide shows some efficacy but with reduced response compared to treatment-naive patients, and might initially cause slight bone density losses at the hip.<br /><br />For denosumab, using it in combination with teriparatide appears effective, demonstrating significant bone density improvements. However, directly switching from denosumab to teriparatide might cause a temporary dip in bone density, particularly at the hip.<br /><br />Post-teriparatide, transitioning to an anti-resorptive agent is crucial to maintain bone density gains. Switching from teriparatide to agents like romosuzumab shows promise, though the opposite sequence seems less effective.<br /><br />Audience inquiries covered topics such as long-term treatment strategies, risk evaluation, and the practicality of drug holidays. Dr. Shibli Rahal emphasized patient-specific approaches and that osteoporosis requires continuous management akin to chronic conditions.

Meta Tag

Concept Bone Remodeling

Concept Teriparatide

Concept Osteoblast

Concept Osteoclast

Concept Antiresorptive Agent

Keywords

osteoporosis

teriparatide

bisphosphonates

denosumab

bone density

endocrinologist

osteoanabolic

anti-resorptive

romosuzumab

treatment strategies

Bone Remodeling

Teriparatide

Osteoblast

Osteoclast

Antiresorptive Agent


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274